Shots:

• The P-III trial evaluates the efficacy and safety of REGEN-COV (casirivimab and imdevimab- 1200/2400mg) vs PBO in a non-hospitalized patient with COVID-19
• The trial met its 1EPs & 2EPs i.e.- 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients & the safety profile was consistent with a previously reported data
• Additionally- multiple analyses showed that the Ab cocktail retains potency against the variants of concern circulating within the US. REGEN-COV is available for free to eligible patients in the US as part of a US government-funded program

  | Ref: PR Newswire | Image: The Print